INT225216

Context Info Confidence 0.42 First Reported 2008 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 2 Disease Relevance 3.16 Pain Relevance 0.15

nucleoplasm (Cdkn2a) aging (Cdkn2a) DNA binding (Cdkn2a) protein complex (Cdkn2a) cytoplasm (Cdkn2a) nucleolus (Cdkn2a)

Cdkn2a (Mus musculus)

Pain Link Frequency Relevance Heat imagery 62 78.64 Spinal cord 8 5.00 trigeminal ganglion 4 5.00 Central nervous system 4 5.00 fifth nerve 4 5.00 anesthesia 2 5.00 Inflammation 2 5.00 isoflurane 2 5.00 cva 2 5.00

Disease Link Frequency Relevance Heat Cancer 76 100.00 Meningioma 182 99.28 Carcinoma 2 94.60 Liver Cancer 4 92.56 Osteoma 4 91.88 Neurofibromatosis 2 18 90.72 Congenital Anomalies 4 84.36 Hydrocephalus 8 78.16 Hyperplasia 8 5.00 Metaplasia 6 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Altogether, these data indicate that in the mouse homozygous inactivation of p16ink4 tumor suppressor gene, with retained p19Arf function, synergizes with Nf2 loss in meningioma initiation, but not in meningioma progression.

Negative_regulation (synergizes) of Negative_regulation (retained) of p19Arf associated with meningioma and cancer

1) Confidence 0.42 Published 2008 Journal Brain Pathology (Zurich, Switzerland) Section Body Doc Link PMC2253711 Disease Relevance 1.57 Pain Relevance 0.08

Altogether, these data indicate that in the mouse homozygous inactivation of p16ink4 tumor suppressor gene, with retained p19Arf function, synergizes with Nf2 loss in meningioma initiation, but not in meningioma progression.

Negative_regulation (synergizes) of Negative_regulation (inactivation) of p16ink4 associated with meningioma and cancer

2) Confidence 0.42 Published 2008 Journal Brain Pathology (Zurich, Switzerland) Section Body Doc Link PMC2253711 Disease Relevance 1.59 Pain Relevance 0.08

General Comments

This test has worked.